Recordati

REC

IT0003828271

Pharmaceuticals

Market Closed - Borsa Italiana Other stock markets 11:44:59 2025-01-13 am EST			After market 02:15:59 pm
52.60 ^EUR	-1.41%		52.78	+0.33%

Jan. 03	Indices expected to fall; euro still weak	AN
Jan. 02	Europeans in the green; at the top Saipem, on the bottom BPER	AN

Recordati-Angelini, possible merger in pharmaceutical sector

November 27, 2024 at 12:46 am EST

(Alliance News) - Recordati Spa, controlled by CVC Capital Partners, and Angelini Pharma are considering a possible merger to create Europe's largest generic drug group, Il Sole 24 Ore reported Wednesday.

Talks are still at a preliminary stage and do not guarantee an agreement, according to Bloomberg. The main node concerns governance between the Angelini family and CVC, which is seeking a strategy to divest after nearly seven years.

With a capitalization of more than EUR10.00 billion, Recordati could opt for a large merger or consider involving an Abu Dhabi sovereign wealth fund. A sale to other private equity funds appears less likely.

Also among the options is refinancing the Recordati bond maturing this year. Options remain open, but for now none prevails.

By Antonio Di Giorgio, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Go to the original article.
Legal disclaimer

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	RECORDATI	52.60EUR	-1.41%	+1.54%	11.16B
	CVC CAPITAL PARTNERS PLC	20.60EUR	-1.15%	-4.36%	22.67B

Latest news about Recordati

Indices expected to fall; euro still weak	Jan. 03	AN
Europeans in the green; at the top Saipem, on the bottom BPER	Jan. 02	AN
Milan stock market positive, good cars with Europe, brisk Tim	Dec. 13	RE
Mib veers into red; up Moncler, down Leonardo	Dec. 09	AN
Mib lone in green; focus on French vote	Dec. 04	AN
Europeans in green, Korea tensions push Brent	Dec. 03	AN
Italian stock market maglia rosa; Mib at 33,900	Dec. 03	AN
Stock markets in the green; Amplifon leads the rises on the Mib.	Dec. 03	AN
Futures up slightly; focus on French crisis	Dec. 03	AN
Business Square in the green; up Nexi, down Stellantis	Dec. 02	AN
Stock markets contrast; down Italy unemployment	Dec. 02	AN
Bags in red pre-PMI; eyes on Stellantis	Dec. 02	AN
Recordati takes over Enjaymo and expects strong revenue boost	Nov. 29	AN
Recordati-Angelini, possible merger in pharmaceutical sector	Nov. 27	AN
Recordati investor CVC taps up potential buyers of drugs group, rival says	Nov. 26	RE
European indexes expected to be in positive territory	Nov. 25	AN
European stock exchanges in green; euro at two-year low	Nov. 22	AN
Only Terna up on Mib; down on banks	Nov. 19	AN
Mib in negative territory; bad banking sector	Nov. 19	AN
Trump makes Wall Street shine and depresses Europe	Nov. 11
Futures expect stock exchanges to rise markedly	Nov. 11	AN
Mib down, financial stocks weigh.	Nov. 08	AN
Italy's Recordati sees no impact from potential US pharma tariffs	Nov. 08	RE
Global markets live: Airbnb, Motorola, Blackrock, P&G, Leonardo...	Nov. 08
Recordati Industria Chimica e Farmaceutica S.p.A., Nine Months 2024 Earnings Call, Nov 08, 2024	Nov. 08

Chart Recordati

Duration

Period

REC: Dynamic Chart

Company Profile

Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (65.7%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.; - medicines for rare diseases (34.3%). Net sales are distributed geographically as follows: Italy (15.2%), Europe (56.4%), America (19%), Asia and Oceania (6.7%) and Africa (2.7%).

Employees

4,455

Sector

Pharmaceuticals

Calendar

2025-01-12 - JP Morgan Healthcare Conference

More about the company